Table 7 The clinical-stage antibody fragments and their derivatives for cancer treatment
From: Emerging new therapeutic antibody derivatives for cancer treatment
Name | Format | Target | Indication(s) | Status | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|
Copper Cu 64-DOTA-B-Fab | Fab | CA6 | Ovarian carcinoma Breast carcinoma | Phase I | NCT02708511 |
CSR02-Fab-TF | Fab | PLVAP | Hepatocellular carcinoma (HCC) | Early Phase I | NCT04601428 |
Ranibizumab | Fab | VEGF | Uveal melanoma | Phase IV | NCT00540930 |
Naptumomab estafenatox | Fab and SEA fusion protein | 5T4 | Renal cell carcinoma | Phase II Phase III | NCT00420888 |
IMCgp100 | Monoclonal TCR anti-CD3 scFv fusion protein | CD3 | Advanced metastatic melanoma | Early Phase I | NCT01209676 |
L19-IL2 | Recombinant scFv | EDB | Solid tumor | Phase I | NCT02086721 |
rM28 | Bispecific scFv | CD28/HMV-MAA | Malignant melanoma | Phase I | NCT00204594 |
D2C7-IT | scFv-based immunotoxin | EGFRwt and EGFRvIII | Recurrent malignant glioma | Phase I | NCT02303678 |
NM21–1480 | Trispecific scFv fusion protein | PD-L1/4–1BB/HSA | Advanced solid tumor | Phase I Phase II | NCT04442126 |
Vicinium | scFv-based immunotoxin | EpCAM | Bladder cancer | Phase III | NCT02449239 |
[124 I] PSCA-Minibody | Minibody | PSCA | Prostate cancer Pancreatic cancer Bladder cancer | Phase I | NCT02092948 |
6B11-OCIK | Minibody | 6B11 | Recurrent platinum-resistant ovarian cancer | Phase I | NCT03542669 |
T84.66 | Iodine I 123 anti-CEA recombinant diabody | CEA | Colorectal cancer | Phase I | NCT00647153 |
BCMA VHH CAR-T Cell | VHH | BCMA | Relapsed/refractory myeloma | Phase I | NCT03664661 |
CD19/20 bispecific VHH-derived CAR-T Cells | VHH | CD19/CD20 | Refractory/relapsed B cell lymphoma | Phase I | NCT03881761 |
ALX-0651 | VHH | CXCR4 | Healthy volunteers | Phase I | NCT01374503 |
αPD1-MSLN-CAR T cells | Secreting PD-1 VHHs | MSLN | Non-small cell lung cancer Mesothelioma | Early Phase I | NCT04489862 |
Colorectal cancer Ovarian cancer | NCT04503980 | ||||
[131I]-SGMIB anti-HER2 VHH1 | VHH | HER2 | Healthy volunteers Breast cancer | Phase I | NCT02683083 |
68-Ga NOTA-anti-MMR-VHH2 | VHH | MMR | Malignant solid tumor Breast cancer Head and neck cancer Melanoma (skin) | Phase I/IIa | NCT04168528 |
68-GaNOTA-anti-HER2 VHH1 | VHH | HER2 | Metastatic breast carcinoma Locally advanced breast cancer | Phase II | NCT03924466 |
Breast neoplasm Breast carcinoma Receptor, ErbB-2 | Phase II | NCT03331601 | |||
99mTc-MIRC208 | VHH-based radiotracer | HER2 | HER2-positive cancer | Preclinical | NCT04591652 |
TAS226 | Tetravalent VHH | DR5 | Advanced solid tumors | Phase I | NCT01529307 |
